Offer - Urjas Oil for just ₹ 1 X
Rischro 1 Tablet is a prescription medicine that is available as a Tablet. Primarily, it is used for the treatment of Schizophrenia. The alternative uses of Rischro 1 Tablet have also been explained below.
The optimal dosage of Rischro 1 Tablet is largely dependent on the individual's body weight, medical history, gender and age. Individual symptoms and route of administration also determines the right dosage. For detailed information on this, read through the dosage section.
Some other side effects of Rischro 1 Tablet have been listed ahead. Normally, these side effects of Rischro 1 Tablet are not long lasting and go away when the treatment is finished. Please speak with your doctor if these side effects worsen or persist for a longer duration.
It is also important to note that Rischro 1 Tablet has a Moderate effect for pregnant women and Severe effect on lactating mothers. Further, the section on Rischro 1 Tablet related warnings talks about Rischro 1 Tablet's effects on the liver, heart and kidney.
Rischro 1 Tablet is not recommended if you suffer from certain medical conditions as it can have adverse effects. Tardive Dyskinesia, Kidney Disease, Liver Disease are examples of such conditions. Some other conditions that can be affected by Rischro 1 Tablet are listed in the contraindications section below.
Drug reaction of Rischro 1 Tablet with other medicines has been reported. Refer to the list below for further details.
You should also be aware that Rischro 1 Tablet is not safe while driving, and is not addiction.
Rischro 1 Tablet is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
13 - 18 years (Adolescent) |
|
2 - 12 years (Child) |
|
Is the use of Rischro 1 Tablet safe for pregnant women?
Rischro can have harmful effects in pregnant women. If you experience any discomfort after using Rischro, then discontinue the use and take your doctor's advice.
Is the use of Rischro 1 Tablet safe during breastfeeding?
Rischro should not be taken without taking your doctor's advice, as it may have severe side effects on breastfeeding women.
What is the effect of Rischro 1 Tablet on the Kidneys?
Rischro may have mild side effects on the kidneys.
What is the effect of Rischro 1 Tablet on the Liver?
Rischro is rarely harmful for the liver.
What is the effect of Rischro 1 Tablet on the Heart?
Very few cases of side effects of Rischro on the heart have been reported.
If you are suffering from any of the following diseases, you should not take Rischro 1 Tablet unless your doctor advises you to do so -
Is this Rischro 1 Tablet habit forming or addictive?
Rischro 1 Tablet is not addictive in nature.
Is it safe to drive or operate heavy machinery when consuming?
After taking Rischro 1 Tablet you may feel sleepy. So it is not advised to perform these activities.
Is it safe?
Rischro 1 Tablet is safe but it is important to consult a doctor before taking it.
Is it able to treat mental disorders?
Rischro 1 Tablet has been seen to have positive effect on patients with mental disorders.
Interaction between Food and Rischro 1 Tablet
Taking Rischro 1 Tablet with some specific foods may delay its effect. Talk to your doctor about this.
Interaction between Alcohol and Rischro 1 Tablet
Taking alcohol with Rischro 1 Tablet can be dangerous.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Risperdal® (risperidone)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 441-442
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1101-1103